ValuEngine cut shares of Oxford Biomedica (OTCMKTS:OXBDF) from a hold rating to a sell rating in a research report report published on Wednesday morning.

A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Oxford Biomedica from a buy rating to a hold rating in a research report on Wednesday, September 6th. HC Wainwright reiterated a buy rating on shares of Oxford Biomedica in a research report on Tuesday, October 31st.

Shares of Oxford Biomedica (OXBDF) traded down $0.02 during midday trading on Wednesday, hitting $0.13. 66,700 shares of the stock were exchanged, compared to its average volume of 10,349. Oxford Biomedica has a 1-year low of $0.04 and a 1-year high of $0.16.

ILLEGAL ACTIVITY WARNING: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://theolympiareport.com/2018/01/04/oxford-biomedica-oxbdf-downgraded-to-sell-at-valuengine.html.

About Oxford Biomedica

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.